New trial
Phase I Study: Safety and Feasibility of IL-8 Receptor Modified CD70 CAR T Therapy in pHGG
- Trial ID
- NCT06946680 on ClinicalTrials.gov
- Cancer type
- Brain & CNS Tumors
- Published in
- New in Oncology - May 14, 2025
University of Florida is assessing the safety and feasibility of autologous, IL-8 receptor (CXCR2) modified CD70 CAR T cells in pediatric high-grade gliomas, with dose escalation across three cohorts (1x10^6, 1x10^7, and 1x10^8 cells/kg).
More in brain and CNS tumors
-
Trial result · Oct 15, 2026 · NCT04365374
Cesium-131 collagen “GammaTile” brachytherapy cuts surgical-bed recurrence vs post-op SRT in resected brain mets -
Trial result · Oct 15, 2026 · NCT03946527
Lanreotide (somatostatin analog) shows disease stabilization in advanced PPGL in a Phase 2 preprint -
New trial · Oct 15, 2026 · NCT07831772
REMIND feasibility study tests a single maintenance IMRT fraction after temozolomide-based treatment in glioblastoma -
New trial · Oct 15, 2026 · NCT07664176
Phase 1 nivolumab plus focused ultrasound and microbubbles tests blood-brain barrier opening in recurrent pediatric brain tumors -
New trial · Oct 15, 2026 · NCT07831369
Phase 2 VISTA combines valproic acid, irinotecan, and simvastatin for recurrent malignant glioma